Close Menu
    What's Hot

    Fujifilm UK Pension Scheme Completes Bulk Purchase Annuity Transaction With Royal London

    November 11, 2026

    Clariant Pension Plan Completes Bulk Purchase Annuity Transaction With M&G

    November 11, 2026

    Editor’s Letter – Volume 2, Issue 11, November 2026

    November 11, 2026
    X (Twitter) LinkedIn
    Longevity & Mortality Investor
    • Home
    • Coverage
      1. Life Insurance Capital Solutions
      2. Life Insurance
      3. Longevity and Mortality Risk Transfer
      4. Mortality
      5. Secondary Life Markets
      6. View All

      Symetra and TIAA Partner To Launch Mariner Re

      October 27, 2026

      Chariot Re Announces Fourth Reinsurance Transaction, First Covering Japanese Liabilities

      October 15, 2026

      Pacific Life Re Executes First Asset-Intensive Reinsurance Transaction in Hong Kong

      September 9, 2026

      Bermuda Life & Annuity Sidecar Market Quadruples as Alternative Asset Manager/Life Insurance Convergence Continues

      September 9, 2026

      Q&A: Alexandr Dudarev, CEO, Inshurik

      October 28, 2026

      Is Dementia the Next Big Longevity Event?

      October 15, 2026

      US Individual Life Insurance Sales Continue Growth Trend in the Second Quarter

      August 13, 2026

      Shaping the Future of Health Insurance Through Innovation and Analytics

      June 10, 2026

      Fujifilm UK Pension Scheme Completes Bulk Purchase Annuity Transaction With Royal London

      November 11, 2026

      Clariant Pension Plan Completes Bulk Purchase Annuity Transaction With M&G

      November 11, 2026

      Sponsor Demand Intact as US Pension Risk Transfer Market Prepares for Busy Year-End

      November 11, 2026

      Delcam Retirement Benefits Scheme Completes Bulk Purchase Annuity Transaction With Royal London

      November 5, 2026

      Record Low Mortality Rates So Far in 2026 in England and Wales, Says CMI

      October 12, 2026

      Record Low Mortality Rates So Far in England and Wales in 2026

      July 9, 2026

      Organ Transplant Improvements Test Life Expectancy Assessment Models

      July 8, 2026

      The Pursuit of Everlasting Life Unlikely to Shift Actuarial Models

      June 10, 2026

      Global Equity Release Market Participants Remain Bullish Despite Macro Headwinds

      November 11, 2026
      Litigation

      Litigation Update: Estate of Long v. Wells Fargo Bank, N.A.

      November 11, 2026

      Life Insurance Settlement Association Announces New Chair, Composition of Board for 2027

      November 11, 2026

      UK Equity Release Activity Nudges Higher in Third Quarter

      October 28, 2026

      Fujifilm UK Pension Scheme Completes Bulk Purchase Annuity Transaction With Royal London

      November 11, 2026

      Clariant Pension Plan Completes Bulk Purchase Annuity Transaction With M&G

      November 11, 2026

      Editor’s Letter – Volume 2, Issue 11, November 2026

      November 11, 2026

      Global Equity Release Market Participants Remain Bullish Despite Macro Headwinds

      November 11, 2026
    • Events
    • Latest Issues

      Editor’s Letter – Volume 2, Issue 11, November 2026

      November 11, 2026
      Life Risk News Editors Letter

      Editor’s Letter – Volume 2, Issue 10, October 2026

      October 15, 2026

      Editor’s Letter – Volume 2, Issue 9, September 2026

      September 9, 2026

      Editor’s Letter – Volume 2, Issue 8, August 2026

      August 12, 2026

      Editor’s Letter – Volume 2, Issue 7, July 2026

      July 8, 2026
    • Contact Us
    Newsletter
    Longevity & Mortality Investor

    LE Mortality Tables and Underwriting

    Mortality Secondary Life Markets July 12, 2023By Traci Davis
    Share
    Twitter LinkedIn Email

    As long as there has been a life settlement market, there has been disagreement over the ‘best’ or appropriate mortality tables for determining life expectancy. The subject has been the source of countless white papers, articles, and verbal sparring during industry panel discussions between actuaries, underwriters, and researchers representing Life Expectancy Provider (LEP) firms. As an underwriting professional, I always come back to what I have always felt to be a relevant stance, which is: “You can have the best mortality table in the business, but if the risk assessment applied by the underwriter is incorrect, the output from the table is going to be worthless.”

    Historically, the relationship between actuarial and underwriting professionals has been symbiotic on the life insurance side. We develop our work in the same ecosystem, and both professions’ decisions will affect each other’s assumptions. However, it is critical to distinguish that actuarial philosophy is based on mathematical theory, based on large homogenous data populations. In contrast, the underwriting philosophy is based on health impairments with unique factors reflected at an individual applicant or insured level. So, when actuarial assumptions do not come to fruition, there is a deep dive into how the individualised risks, with shared components, were underwritten. These typically cause changes reflected in the mortality tables. Essentially, the underwriting process drives mortality table changes and outcomes.

    Consider the following: actuaries live in a world of large numbers. They typically relate it to ‘if we start with 1,000 lives’ when they break down examples. However, underwriters, while understanding that debit and credit methodology takes the law of large numbers into account, we live in a world of assessing the individual in front of us and all of the aspects of the risk that may be relative to the impairment but also unique to that individual. 

    For example, when you take the broad category of coronary artery disease, actuarial science (for developing appropriate outcomes relative to the risk) will start with the Framingham heart study out of MA (circa 1948). Framingham has been a serial decade study of individuals and their family members tracking specific cardiac risk factors over generations, starting with over 5,200 original participants. This study works well, from the diversity, population size, and duration (years of study time) for actuarial science, to determine, with reasonable certainty, the mortality impact of specific risk factors for developing disease and stability (or progression) of disease over time. This insight into crucial risk components is incorporated into underwriting manuals that guide the underwriter in capturing all relative risk factors the same way for every cardiac risk. However, the studies, the actuarial science, and the manual do not provide insight into the nuance of each risk. Meaning the data will indicate in broad terms a potential outcome. Still, the information underwriters develop on applicants or insureds is not purely broad-based impairment data; it is very specific to that individual.

    What does this intersection of actuarial science versus underwriting do? Suppose you are an underwriter that ‘underwrites by the book’ and applies what an underwriting manual suggests without considering the unique factors of the individual. In that case, there is a high probability that you will over or under-assess the risk (by applying too many or too few debits or credits). Then, when using that outcome in the actuarial table, which could be the most relevant table for the population of risk being assessed, the estimated life expectancy may be useless in pinpointing the risk.

    Based on life settlement-specific information noted in various articles, white papers, and presentations I ingest weekly, I have yet to see anything that focuses on the underwriting of the risk and how it impacts the mortality outcomes. Instead, most of the information is a continued argument over which table is best; Social security population being more relevant than insured lives tables, not sharing mortality tables because it is the ‘secret sauce’ of the process, layers of different tables to fit the risk, etc.

    While actuarial science is critical and has a place in developing appropriate tables based on the unique factors of the population being underwritten, underwriting is where the discussion should focus, even if you are working with a LEP that establishes all outcomes on the table. If you do not understand the underwriting methodology or philosophy, and you are not being provided that insight by the LEPs you are working with (assuming you are speaking with someone that is a professional and certified Actuary or a Certified Underwriting Professional), it is to be expected that the outcomes seen in the block of business you are managing will be not what you thought you’d see.

    Traci E. Davis, Certified FALU, FLMI, ACS is Chief Customer Whisperer, Chief Underwriter at Valkyrie Limited


    Any views expressed in this article are those of the author(s) and do not necessarily reflect the views of Life Risk News or its publisher, the European Life Settlement Association

    2023 - July Commentary Life Settlements Longevity Risk Volume 2 Issue 7 - July 2023
    Share. Twitter LinkedIn Email

    Related Posts

    Litigation

    Litigation Update: Estate of Long v. Wells Fargo Bank, N.A.

    November 11, 2026By Greg Winterton

    Life Insurance Settlement Association Announces New Chair, Composition of Board for 2027

    November 11, 2026By LMI Newsdesk

    New Report Highlights Tighter Regulatory Oversight of Asset-Intensive Reinsurance

    October 28, 2026By Greg Winterton

    New Report Suggests Life Settlement Market Poised for Long-Term Expansion

    October 15, 2026By Greg Winterton
    Latest Issue

    Global Equity Release Market Participants Remain Bullish Despite Macro Headwinds

    November 11, 2026
    Litigation

    Litigation Update: Estate of Long v. Wells Fargo Bank, N.A.

    November 11, 2026

    Sponsor Demand Intact as US Pension Risk Transfer Market Prepares for Busy Year-End

    November 11, 2026

    New Report Highlights Tighter Regulatory Oversight of Asset-Intensive Reinsurance

    October 28, 2026
    Ad

    Where Longevity and Mortality Meet the Markets
    ISSN 2978-5219

    X (Twitter) LinkedIn
    Coverage
    • Life Insurance Capital Solutions
    • Life Insurance
    • Longevity and Mortality Risk Transfer
    • Mortality Risk
    • Secondary Life Markets
    More Info
    • Home
    • About Us
    • Contact Us
    • Guest Articles
    • Submit Story Idea
    Our Newsletter
    Get the latest industry news, commentary and events from the Longevity & Mortality Investor directly into your inbox. Why not sign up today?

    © 2026 Longevity & Mortality Investor. Website by Kavells.
    • Sitemap
    • Privacy Policy
    • Copyright Notice
    • Terms & Conditions

    Type above and press Enter to search. Press Esc to cancel.